Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,816.89
(
-0.11%
)
US TECH 100
24,499.60
(
0.38%
)
Dow Jones
47,916.57
(
-0.56%
)
Brent Oil
92.41
(
0.00%
)
Bitcoin
73,643.43
(
0.91%
)
News Focus
News Focus
Post# of 257382
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122860
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 239626

Saturday, 03/19/2022 1:37:44 PM

Saturday, March 19, 2022 1:37:44 PM

Post# of 257382
FDA approves BMY’s Opdualag—a_co-formulated_FDC_of Opdivo and anti-LAG-3 relatlimab—in first-line melanoma:

https://finance.yahoo.com/news/u-food-drug-administration-approves-222900124.html

The approval is based on the RELATIVITY-047 trial, which tested Opdivo + relatlimab against Opdivo monotherapy and had a PFS HR=0.75 (#msg-163914232).

In first-line melanoma, Opdulag offers comparable efficacy to Opdivo + Yervoy with less toxicity.

My abbreviated take:
https://twitter.com/DewDiligence/status/1395141087413538822

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today